Differential development of adenosine A1 and A2b receptors in the rat duodenum

The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications

Gut homeostasis results from complex neuro-immune interactions aimed at triggering stereotypical and specific programs of coordinated mucosal secretion and powerful motor propulsion. A prominent role in the regulation of this highly integrated network, comprising a variety of immune/inflammatory cells and the enteric nervous system, is played by purinergic mediators. The cells of the digestive tract are literally plunged into a "biological sea" of functionally active nucleotides and nucleosides, which carry out the critical task of driving regulatory interventions on cellular functions through the activation of P1 and P2 receptors. Intensive research efforts are being made to achieve an integrated view of the purinergic system, since it is emerging that the various components of purinergic pathways (i.e., enzymes, transporters, mediators and receptors) are mutually linked entities, deputed to finely modulating the magnitude and the duration of purinergic signaling, and that alterations occurring in this balanced network could be intimately involved in the pathophysiology of several gut disorders. This review article intends to provide a critical appraisal of current knowledge on the purinergic system role in the regulation of gastrointestinal functions, considering these pathways as a whole integrated network, which is capable of finely controlling the levels of bioactive nucleotides and nucleosides in the biophase of their respective receptors. Special attention is paid to the mechanisms through which alterations in the various compartments of the purinergic system could contribute to the pathophysiology of gut disorders, and to the possibility of counteracting such dysfunctions by means of pharmacological interventions on purinergic molecular targets.

Purinergic mechanisms in the control of gastrointestinal motility

For many years, ATP and adenosine have been implicated in movement regulation of the gastrointestinal tract. They act through three major receptor subtypes: adenosine or P1 receptors, P2X receptors and P2Y receptors. Each of these major receptor types can be subdivided into several different classes and is widely distributed amongst various neurons, muscle types, glia and interstitial cells that regulate intestinal functions. Several key roles for the different receptors and their endogenous ligands have been identified in physiological and pharmacological studies. For example, adenosine acting at A(1) receptors appears to inhibit intestinal motility in various pathological conditions. Similarly, ATP acting at P2Y receptors is an important component of inhibitory neuromuscular transmission, acting as a cotransmitter with nitric oxide. ATP acting at P2X and P2Y(1) receptors is important for synaptic transmission in simple descending excitatory and inhibitory reflex pathways. Some P2Y receptor subtypes prefer uridine nucleotides over purine nucleotides. Thus, roles for UTP and UDP as enteric transmitters in place of ATP cannot be excluded. ATP also appears to be important for sensory transduction, especially in chemosensitive pathways that initiate local inhibitory reflexes. Despite this evidence, data are lacking about the roles of either adenosine or ATP in more complex motility patterns such as segmentation or the interdigestive migrating motor complex. Clarification of roles for purinergic transmission in these common, but understudied, motility patterns will depend on the use of subtype-specific antagonists that in some cases have not yet been developed.

Role of adenosine A2A receptor in the regulation of gastric somatostatin release

Adenosine has been demonstrated to inhibit gastric acid secretion. In the rat stomach, this inhibitory effect may be mediated indirectly by increasing the release of somatostatin-like immunoreactivity (SLI). Results show that adenosine analogs augmented SLI release in the isolated vascularly perfused rat stomach. The rank order of potency of the analogs in stimulating SLI release was 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680) approximately 5'-N-ethylcarboxamidoadenosine > 2-chloroadenosine > R-(-)-N(6)-(2-phenylisopropyl)adenosine >1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-beta-d-ribofuranuronamide > N(6)-cyclopentyladenosine approximately N(6)-cyclohexyladenosine > S-(+)-N(6)-(2-phenylisopropyl) adenosine, suggesting the involvement of the A(2A) receptor. In agreement, 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a] [1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385), an A(2A) receptor antagonist, was shown to abolish the adenosine- and CGS 21680-stimulated SLI release. Immunohistochemical studies reveal the presence of A(2A) receptor immunoreactivity on the gastric plexi and mucosal D-cells, but not on parietal cells and G-cells, suggesting that adenosine may act directly on D-cells or indirectly on the gastric plexi to augment SLI release. The present study also demonstrates that the structure of the mucosal A(2A) receptor is identical to that in the rat brain, and that alternative splicing of this gene does not occur. A real-time reverse transcription-polymerase chain reaction assay has also been established to quantify the levels of A(2A) receptor mRNA. Results show that gastric tissues contained significantly lower levels of A(2A) receptor mRNA compared with the striatum. The lowest level was detected in the mucosa. In conclusion, adenosine may act on A(2A) receptors to augment SLI release and consequently control gastric acid secretion.

Acid-induced mesenteric hyperemia in rats: role of CGRP, substance P, prostaglandin, adenosine, and histamine

Intraduodenal acidification produces a mesenteric hyperemia that is mediated in part by mucosal capsaicin-sensitive afferent nerves and the bradykinin B2 receptor in anesthetized rats. We hypothesized that novel mechanisms mediated by substance P, adenosine, and histamine1 receptors are involved. Confirmation of a role for calcitonin gene-related peptide (CGRP) but not endogenous prostaglandin was also sought. In study 1, vehicle or antagonists (CGRP(8-37), CP 96345) was administered intravenously. Capsaicin or acid was administered intraduodenally, followed by intravenous CGRP or substance P. In study 2, pretreatments included indomethacin, 8-phenyltheophylline, pyrilamine, or the respective vehicles. Acid was then administered intraduodenally. In both studies, superior mesenteric artery blood flow was monitored. In study 1, the antagonists significantly attenuated capsaicin- and acid-induced mesenteric hyperemia. In study 2, the pretreatments did not alter acid-induced hyperemia. The data confirmed the role of CGRP and indicated for the first time an involvement for substance P in acid-induced mesenteric hyperemia.

Extracellular adenosine deprivation induces epithelial differentiation of HT29 cells: evidence for a concomitant adenosine A(1)/A(2) receptor balance regulation

HT29 cells display an undifferentiated phenotype in culture. However, numerous treatments are able to induce both epithelial differentiation and cell growth inhibition. We have previously demonstrated that adenosine and its analogues act through specific adenosine receptors to modulate cell proliferation in HT29 and other human colon adenocarcinoma cell lines. Among the treatments tested, the most potent inhibition of HT29 cell growth was induced by deprivation of extracellular adenosine using adenosine deaminase. Here, we investigated the capacity of adenosine deaminase to initiate epithelial differentiation. After 1 month of daily addition of 10 U/ml adenosine deaminase to the culture medium, HT29 cells were cloned by limited dilution. Among the clones obtained, we focused our attention on clone 13. Microscopic visualization and proliferation studies indicated that cells from this clone grew very slowly and in a pseudo-monolayer, in marked contrast with the situation observed in the mother HT29 cell line. In addition, clone 13 cells displayed epithelial features that mimic the enterocytic differentiation of Caco-2 cells. These modifications were accompanied by dramatic changes in the activity of adenosine receptors, as demonstrated by pharmacological studies. In contrast to the original HT29 cells, clone 13 as well as Caco-2 cells displayed (i) a very low number of adenosine A(1) receptors, and (ii) increases in intracellular cAMP levels when challenged with adenosine analogues. It is hypothesized that a loss of adenosine A(1) receptors, with no change or a concomitant increase in adenosine A(2) receptors, results in the emergence of adenosine A(2) receptor-mediated differentiation and inhibition of proliferation, through a cAMP-dependent pathway.

Transitory expression of the A2b adenosine receptor during implantation chamber development

Adenosine is a short-range signal molecule that surges in the mouse uterus immediately after blastocyst implantation (Blackburn et al. [1992] Dev. Dyn. 194:155-168). The present study has investigated patterns of uterine adenosine receptor expression during early post-implantation development. Strong expression of the A2b adenosine receptor was observed. Utilizing northern blot analysis, in situ hybridization, and immunostaining, the source of expression was mapped to the primary and secondary decidua of the antimesometrial region, between days 4-8 of gestation. Distribution of the A2b receptor protein followed that of the corresponding transcript by about one gestational day and reflected the dynamics of antimesometrial tissue organization during implantation chamber development. Uterine adenosine surges to levels sufficient for A2b receptor engagement during a defined period (i.e., days 4-6) after blastocyst implantation. Decidual A2b receptor expression thus defines a transitory window of murine gestation that corresponds to a period of human gestation encompassing most spontaneous pregnancy losses. Because adenosine receptors are sensitive to metabolically stable adenosine analogues, their differential expression during implantation chamber development may hold therapeutic potential in the prevention of early pregnancy loss. Dev Dyn 1999;216:127-136.

Postnatal development of purinoceptors in rat visceral smooth muscle preparations

1. Adenosine and ATP have well-established functions as neuromodulator and neurotransmitter, respectively, in smooth muscle preparations, and purinergic control may be an early form of autonomic control in both evolution and ontogenesis. 2. This review describes the postnatal development of responses mediated by the various receptors for adenosine and for nucleotides in the rat duodenum, colon, urinary bladder and vas deferens and considers the implications that this development may have for the importance of purinergic control in neonates and adults.

Ontogeny of P2-purinoceptors in the longitudinal muscle and muscularis mucosae of the rat isolated duodenum

1. The ontogeny of P2-purinoceptors in the longitudinal muscle and the muscularis mucosae of the rat isolated duodenum was investigated by use of functional assays in tissues from neonatal animals. The degradation of purinoceptor agonists by the rat duodenum muscularis mucosae was also investigated. 2. In the rat duodenum muscularis mucosae adenosine 5'-(alpha, beta-methylene)triphosphonate (AMPCPP), adenosine 5'-triphosphate (ATP), uridine 5'-triphosphate (UTP) and 2-methylthioadenosine 5'-triphosphate (2-Me-S-ATP) all caused a contraction from day 10 to day 40, day 10 being the earliest age it could be tested. The potency order of agonists above day 25 was AMPCPP > ATP = UTP > 2-Me-S-ATP and this is similar to the potency order previously obtained for the adult tissue. However, in the neonatal tissues below day 20, 2-Me-S-ATP was the most potent agonist and at days 10 and 15 the order was 2-Me-S-ATP > AMPCPP > ATP = UTP. 3. In the rat duodenum muscularis mucosae desensitization was observed with AMPCPP at day 30 but not at day 15. At day 30, cross-desensitization was also observed between AMPCPP and 2-Me-S-ATP but not between AMPCPP and ATP or UTP, whereas no cross-desensitization was observed at day 15 with AMPCPP and any of the agonists. At day 15 and below AMPCPP and 2-Me-S-ATP may therefore both activate P2Y-receptors (2-Me-S-ATP > AMPCPP, no desensitization with AMPCPP) whereas above day 20 the agonists activate P2X-receptors (AMPCPP > 2-Me-S-ATP, desensitization with AMPCPP) which is similar to the adult tissue. Since ATP and UTP were equipotent in the muscularis mucosae and as no cross-desensitization was observed with AMPCPP and UTP or ATP at days 15 or 30, it is likely that ATP and UTP both activate P2U-receptors throughout the ages, as in the adult. 4. The potency of all the agonists in causing contraction in the rat duodenum muscularis mucosae decreased with age. The potency of AMPCPP and 2-Me-S-ATP in causing contractions was highest in the neonates before day 25, and reached values not significantly different from adult by day 30, and the potency of ATP and UTP causing contractions in this tissue was also highest in the neonates at days 10 and 15, and reached values not significantly different from adult by day 20. This suggests either that the receptor populations mediating contraction are highest in the neonates below day 20 or that the agonists are degraded by the muscularis mucosae to a greater extent after day 20. 5. In the rat duodenum muscularis mucosae the degradation of ATP, UTP, 2-Me-S-ATP and AMPCPP was followed by high pressure liquid chromatography at days 15 and 30. ATP was degraded to adenosine 5'-diphosphate (ADP), adenosine 5'-monophosphate (AMP) and inosine with no adenosine being detected, 2-Me-S-ATP was degraded to 2-methylthioadenosine 5'-diphosphate (2-Me-S-ADP), 2-methylthioadenosine 5'-monophosphate (2-Me-S-AMP) and 2-methylthioadenosine (2-Me-S-adenosine), and UTP was degraded to uridine 5'-diphosphate (UDP), uridine 5'-monophosphate (UMP) and uridine. The rate of degradation of these agonists was much faster at day 30 than at day 15, probably due to the increase in the size of the tissue. AMPCPP was also degraded with adenosine 5'-(alpha,beta-methylene)diphosphonate (AMPCP) being detected at both ages. However, at day 30 the rate of degradation of AMPCPP was much slower than for ATP, UTP or 2-Me-S-ATP. 6. In the rat duodenum longitudinal muscle 2-Me-S-ATP and AMPCPP both caused a relaxation with a potency order of 2-Me-S-ATP > AMPCPP, suggesting the activation of P2Y-receptors, as previously found for the adult tissue. Weak relaxations were observed to both the agonists at day 15 (the earliest age it could be studied), and the potency of the agonists reached values not significantly different from adult tissues by day 25. 7. Overall, these results suggest that in the neonatal rat duodenum longitudinal muscle there are P2Y-receptors mediating relaxation and that the receptor population i